Skip to main content

Now live! Explore the program for the upcoming 2024 Global Conference, taking place May 5-8, 2024.

Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky

Podcast Series

Ep. 112: Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky

Episode. 112 : Speed of Science, with Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky

Albert Bourla

Albert Bourla

Chairman and CEO, Pfizer
Alex Gorsky

Alex Gorsky

Chairman and CEO, Johnson & Johnson

“I think history has shown us to have major leaps forward almost after every crisis. Whether it's a war, a natural disaster, or frankly a big challenge such as going to the moon, these kinds of inflection points force us to go in new directions to collaborate and to accelerate technological breakthroughs.” - Alex Gorsky

Two of the most important CEOs in the world today—Pfizer’s Albert Bourla and Johnson & Johnson’s Alex Gorsky—spoke recently with Mike at the Milken Institute’s Future of Health Summit. While Pfizer is already scaling up production and distribution of their mRNA-based vaccine, Gorsky’s company is looking forward to the third-stage clinical trial results for their single dose, vector-based therapy. The unprecedented collaboration fostered at all levels of the biomedical sector has paid dividends, with many more potential treatments to come.

“I'm very proud of what we have been able to achieve,” Albert Bourla tells Mike on the podcast. “We will see many more companies in the next few weeks and months demonstrating similar successes in their projects against COVID because one vaccine or two vaccines will not be enough for the entire world. The world needs options.”